By a News Reporter-Staff News Editor at Cancer Vaccine Week -- A new study on Liver Diseases and Conditions is now available. According to news reporting originating in Beijing, People's Republic of China, by NewsRx journalists, research stated, "Reactivation of hepatitis B virus (HBV) can occur in lymphoma patients infected with HBV when they receive chemotherapy or immunotherapy. Prophylactic administration of lamivudine (LAM) reduces the morbidity and mortality associated with HBV reactivation."
The news reporters obtained a quote from the research from Peking University, "However, what defines HBV reactivation and the optimal duration of treatment with LAM have not yet been clearly established. HBV reactivation may occur due to the cessation of prophylactic LAM, although re-treatment with nucleoside analogs may sometimes result in hepatitis B surface antigen (HBsAg) seroconversion, which is a satisfactory endpoint for the management of HBV infection. We report a case of HBV reactivation in a 68-year-old HBsAg-positive patient who received rituximab-based immunochemotherapy for follicular lymphoma. HBV reactivation developed following cessation of prophylactic LAM therapy. The patient subsequently received treatment with entecavir (ETV), which led to a rapid and sustained suppression of HBV replication and HBsAg seroconversion. We also appraised the literature concerning HBV reactivation and the role of ETV in the management of HBV reactivation in lymphoma patients. A total of 28 cases of HBV reactivation have been reported as having been treated with ETV during or after immunosuppressive chemotherapy in lymphoma patients."
According to the news reporters, the research concluded: "ETV is an efficacious and safe treatment for HBV reactivation following LAM cessation in lymphoma patients treated with rituximab-based immunochemotherapy."
For more information on this research see: Hepatitis B surface antigen seroconversion after HBV reactivation in non-Hodgkin's lymphoma. World Journal of Gastroenterology, 2014;20(17):5165-5170. World Journal of Gastroenterology can be contacted at: Baishideng Publishing Group Inc, 8226 Regency Dr, Pleasanton, CA 94588, USA. (Baishideng Publishing Group - www.wjgnet.com/; World Journal of Gastroenterology - www.wjgnet.com/1007-9327/current.htm)
Our news correspondents report that additional information may be obtained by contacting W.P. Liu, Peking University, Dept. of Infect Dis, Center Liver Dis, Hosp 1, Beijing 100142, People's Republic of China. Additional authors for this research include W. Zheng, Y.Q. Song, L.Y. Ping, G.Q. Wang and J. Zhu (see also Liver Diseases and Conditions).
Keywords for this news article include: Asia, Antineoplastic Monoclonal Antibodies, Antirheumatics, Biotechnology, Drugs, Viral, Beijing, Lymphoma, Oncology, Rituximab, Hematology, Immunology, DNA Viruses, Chemotherapy, Immunotherapy, Medical Devices, Gastroenterology, Immunomodulation, Hepatitis B Virus, Orthohepadnavirus, Biological Factors, Infectious Disease
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC